Noribogaine
ibogaine metab.
What it isThe long-lived active metabolite of ibogaine.
Why it mattersIts persistence explains why a single ibogaine dose is reported to suppress craving for weeks.
What it changesIt shares the QT prolongation that makes ibogaine dangerous, and outlasts the parent by days.
FDA-approved for
- active metabolite of ibogaine (not approved)
NO BOXED WARNINGS
Principal riskIt shares the QT prolongation that makes ibogaine dangerous, and outlasts the parent by days
Classes and tags
Clinical profile
Serotonin and MAOI
Provisional washout figures
Elevating mechanismSRI (noncompetitive)
Evidence confidenceModerate
InterpretationThe principal ibogaine metabolite, ~10x more potent at SERT than the parent. Reframed in 2026 as a "synaptic reuptake inhibitor" (SynRI) for its dual VMAT2 + SERT inhibition at comparable potencies -- a reuptake inhibitor, not a substrate-type releaser.